ClinicalTrials.gg
RecruitingNCT07095426Updated Jul 31, 2025

Impact of Supplemental Fiber on Gut and Vascular Health Related in Obesity Phenotypes

An interventional study of inulin in Metabolic Syndrome, Healthy Participants and Metabolically Healthy Obesity, sponsored by Ball State University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by Ball State University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 578 studies in Metabolic Syndrome with a site in United States — 62 open to participants now, 84 under way, 3 of them phase 3. Metabolic Syndrome · United States.

Planned enrollment
393rd of 490
20 · median 48
Started
2025
with 17 others
No phase
345 of 578
33 open now
Primary completion
2026-11
later than 18 of 82 live
Registered
553rd of 578
by date

Among the 578 studies in Metabolic Syndrome with a site in United States, this one is the 393rd largest by planned enrollment of the 490 interventional ones that give a count, is one of 18 that started in 2025, is one of 345 with no phase, reaches primary completion later than 18 of the 82 other live ones, and was the 553rd registered.

Metabolic Syndrome

2,120 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

62 of the 578 studies in Metabolic Syndrome with a site in United States are open now. Recruiting first, the newest first:

56 more — sign in →

All 62 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 578 studies in Metabolic Syndrome with a site in United States, or all of them as a file.
02

Study summary

Based on prior research, the investigators are interested in whether an intervention targeting gut health (supplemental fiber for 9 weeks total) will improve vascular health in individuals with obesity. Additionally, the investigators are interested in if this response differs based on whether individuals with obesity have very few heart disease risk factors or several heart disease risk factors.

Read the detailed description

The investigators will recruit individuals with obesity (body mass index ≥30 kg/m2) from Ball State University Campus and the surrounding community. Participants will be grouped as "metabolically healthy" (0-1 metabolic syndrome risk factors) or "metabolically unhealthy" (≥2 metabolic syndrome risk factors) Participants will be asked to consume inulin for 9 weeks total. Participants will consume 6g of inulin per day during week 1 as a run-in period. The following 8 weeks participants will consume 12g of inulin per day.

Participants will be asked to report for in-lab assessments/visits before the study begins (baseline), halfway through the intervention which starts following the 1-week run-in period (5 weeks), and at the conclusion of the intervention (9 weeks). At all of these assessments, participants will arrive in the morning (roughly 6-10 AM) having fasted for \~10 hours. We will then collect a blood sample, followed by several vascular measurements including flow-mediated dilation, pulse wave analysis, pulse wave velocity, and an electrocardiogram. Body weight and composition will also be assessed using a bioimpedance scale at each visit. Upon completion of each in-lab visit, participants will be asked to wear an ambulatory blood pressure monitoring device for 24 hours and will complete a 3-day food record. Dual-energy X-ray absorptiometry scans will be used to assess body composition at baseline and final study visits. Participants will provide a stool sample collected at home following baseline and final study visits as an optional procedure.

03

Conditions studied

  • Metabolic Syndrome
  • Healthy Participants
  • Metabolically Healthy Obesity
  • Metabolically Abnormal Obesity

Keywords

  • fiber
  • vascular health
  • gut health
  • inflammation
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are 18-55 years old.
  • Participants is ≥30 kg/m2 - this BMI requirement is due to our research aims.
  • Participants have either 0-1 or 2+ of the following risk factors outside of the normal reference ranges: blood pressure, blood sugar, triglycerides, and HDL-cholesterol.
  • Participants are not pregnant or expecting to become pregnant (females only). •Participants are not (females only).
  • Participants have not been diagnosed with an advanced cardiometabolic condition (e.g., cardiovascular disease, type 2 diabetes).
  • Participants have not been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease, diverticulosis/diverticulitis).
  • Participants do not regularly take anti-inflammatory drugs (more than 2x week) and are willing to suspend use of these medications for 3 days leading up to in-lab visits.
  • Participants do not take weight-loss medications (e.g., Ozempic, Wegovy).
  • Participants do not use tobacco products or any illicit drugs.
  • Participants have not used antibiotics or probiotics in the last month.
  • Participants do not have dietary restrictions prohibiting them from consuming the fiber supplement (e.g., food allergies/intolerance).
  • Participants do not have a pacemaker.
  • Participants are able to lie on their back (supine position) in the dark for at least 10 minutes (related to vascular measurements).

Exclusion criteria

Exclusion Criteria:

  • Participants are not 18-55 years old.
  • Participants is not ≥30 kg/m2 - this BMI requirement is due to our research aims.
  • Participants do not have either 0-1 or 2+ of the following risk factors outside of the normal reference ranges: blood pressure, blood sugar, triglycerides, and HDL-cholesterol.
  • Participants are pregnant or expecting to become pregnant (females only).
  • Participants are (females only).
  • Participants have been diagnosed with an advanced cardiometabolic condition (e.g., cardiovascular disease, type 2 diabetes).
  • Participants have been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease, diverticulosis/diverticulitis). •Participants regularly take anti-inflammatory drugs (more than 2x week) and are not willing to suspend use of these medications for 3 days leading up to in-lab visits.
  • Participants take weight-loss medications (e.g., Ozempic, Wegovy).
  • Participants use tobacco products or any illicit drugs.
  • Participants have used antibiotics or probiotics in the last month.
  • Participants have dietary restrictions prohibiting them from consuming the fiber supplement (e.g., food allergies/intolerance).
  • Participants have a pacemaker.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Inulin Supplement

    Participants will consume 6g of pre-portioned powdered inulin from chicory root daily for one week followed by 12g daily for eight weeks. Participants will fully dissolve it into a habitual cool or room temperature beverage to drink around the same time each day.

    Dietary Supplement: inulin

Interventions

  • Dietary supplementinulin

    6g inulin from chicory root per day for one week and 12g inulin per day for eight weeks dissolved into cool or room temperature liquid

06

What researchers measure

Primary outcomes

  1. Serum Soluble Cluster of Differentiation 14 (sCD14)

    The investigators will measure fasting sCD14 at each visit. These measurements will take place immediately and a complete dataset will be compiled upon study completion.

    Time frame: Through study completion, up to 1.5 years.

  2. Serum Lipopolysaccharide Binding Protein (LBP)

    The investigators will measure fasting LBP at each visit. These measurements will take place immediately and a complete dataset will be compiled upon study completion.

    Time frame: Through study completion, up to 1.5 years.

  3. Serum C-Reactive Protein (CRP)

    The investigators will measure fasting CRP at each visit. These measurements will take place immediately and a complete dataset will be compiled upon study completion.

    Time frame: Through study completion, up to 1.5 years.

  4. Heart Rate Variability (HRV)

    The investigators will measure HRV at each visit. These measurements will take place immediately and a complete dataset will be compiled upon study completion.

    Time frame: Through study completion, up to 1.5 years.

  5. Flow-Mediated Dilation (FMD)

    The investigators will measure FMD at each visit. These measurements will take place immediately and a complete dataset will be compiled upon study completion.

    Time frame: Through study completion, up to 1.5 years.

  6. Pulse Wave Velocity (PWV)

    The investigators will measure PWV at each visit. These measurements will take place immediately and a complete dataset will be compiled upon study completion.

    Time frame: Through study completion, up to 1.5 years.

  7. Aortic Aumentation

    The investigators will measure aortic augmentation at each visit. These measurements will take place immediately and a complete dataset will be compiled upon study completion.

    Time frame: Through study completion, up to 1.5 years.

  8. Augmentation Index (AIx)

    The investigators will measure AIx at each visit. These measurements will take place immediately and a complete dataset will be compiled upon study completion.

    Time frame: Through study completion, up to 1.5 years.

Secondary outcomes

  1. Blood Pressure

    The investigators will measure peripheral, central, and ambulatory blood pressure at each visit. These measurements will take place immediately and a complete dataset will be compiled upon study completion.

    Time frame: Through study completion, up to 1.5 years.

  2. Glucose

    The investigators will measure fasting glucose at each visit. These measurements will take place immediately and a complete dataset will be compiled upon study completion.

    Time frame: Through study completion, up to 1.5 years.

  3. High-Density Lipoprotein Cholesterol (HDL-C)

    The investigators will measure fasting HDL-C at each visit. These measurements will take place immediately and a complete dataset will be compiled upon study completion.

    Time frame: Through study completion, up to 1.5 years.

  4. Triglycerides

    The investigators will measure fasting triglycerides at each visit. These measurements will take place immediately and a complete dataset will be compiled upon study completion.

    Time frame: Through study completion, up to 1.5 years.

  5. Digestive Symptoms

    The investigators will measure digestive symptoms at each visit. These measurements will take place immediately and a complete dataset will be compiled upon study completion.

    Time frame: Through study completion, up to 1.5 years.

Other outcomes

  1. Body Composition

    The investigators will measure body composition using bioelectrical impedance and waist circumference at each visit, and dual-energy X-ray absorptiometry at the baseline and final visits. These measurements will take place immediately and a complete dataset will be compiled upon study completion.

    Time frame: Through study completion, up to 1.5 years.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Nov 2026, 18 months after the start.

Of 627 non-industry interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 18 months is close to that.

Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2025
First posted
Jul 31, 2025
StartActual
May 20, 2025
Primary completionEst.
Nov 2026
CompletionEst.
May 2027
Last update
Jul 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07095426
Lead sponsor
Ball State University
Responsible party
Bryant Keirns (Assistant Professor, Ball State University) — Principal investigator
First posted
Jul 31, 2025
Start date
May 20, 2025
Primary completion
Nov 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Jul 31, 2025

Study contacts

Bryant Keirns, PhD
Contact
bryant.keirns@bsu.edu
765-285-8356
Bryant Keirns, PhD
principal investigator · Ball State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inulin

Start the discussion